about
Population pharmacokinetics of bevacizumab in cancer patients with external validationOzanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsiesThe pharmacokinetics of methadone and its metabolites in neonates, infants, and childrenPrediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescentsThe present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Romiplostim dose response in patients with immune thrombocytopenia.Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinQuantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogsAn integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children.Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamicsPopulation pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Tips and traps analyzing pediatric PK data.IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approachA Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer PatientsEvaluation of different tests based on observations for external model evaluation of population analyses.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.PKreport: report generation for checking population pharmacokinetic model assumptions.Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment.Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladderEffects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measurePopulation pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Automatic data binning for improved visual diagnosis of pharmacometric models.Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus.Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.Covariates of intravenous paracetamol pharmacokinetics in adultsA pharmacokinetic PET study of NK₁ receptor occupancy.Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti -tuberculosis therapy.Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisPopulation pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant periodMarginal increase of sunitinib exposure by grapefruit juice.A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.Population pharmacokinetics of mavacoxib in osteoarthritic dogs.Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals
P2860
Q26779580-DB6D9F19-896B-4415-9B33-6A5344DE386CQ28543591-F6B670AF-9CE2-4A8D-AD9C-CF779BE3C0E9Q30393865-28BFBC4F-2913-40A7-8488-0A70ED2950A1Q30499990-57716FCA-11C9-4C68-A30D-9B68EA04CC7FQ30832465-C7D922D6-D4ED-4C3C-B9F8-DEE6F457FA98Q31118795-7CF1A5C7-ED6D-4B4E-9F35-307720325F24Q33398730-2E1A43D3-FB4F-43C1-A888-CE01A0434DF1Q33427607-FECD0D80-D44F-48DB-AD20-00469CD33AA6Q33524423-E8A42917-255B-430A-80DE-66259C4FDCF8Q33595343-C492FF88-87ED-4D99-9D36-BA8C47D2B4DFQ33633622-70841444-C8E4-42C1-A9FB-8B7BB415C167Q33642622-E7FB9AAA-A502-4498-87D0-C688FFEAC898Q33743151-13F4C888-8107-41FD-AF40-6A26A4DBB917Q33795052-72348E22-A27F-4EF6-8E9C-756BB2D376BAQ33820152-0E85C4BB-8E54-451C-8679-9201700B840BQ33840340-124F672C-55B8-41F9-ACC3-6813414EBEFCQ33845632-D5E687CC-2080-49D8-B3B7-9E2CDD81F725Q33869167-165059FA-E999-41FC-80E9-F40231AE1A30Q33888004-9ADC35DC-2BCE-4C72-BA6D-9F3CFA80C5C8Q33891532-EE6F07FA-6743-496F-A96D-8664CC6F9A43Q33901595-92300196-11CA-4A39-9CBD-3D175C4DA521Q33925036-882003EC-F4B4-4F51-9CAA-80C6345A9B67Q34019358-24DECC28-287D-4B1E-85BD-A2808FC07DF6Q34045240-0CCCFE97-B46E-447E-B798-BD05B63CF1EAQ34055606-6462729C-2CFC-46EE-B405-EFAB5EEE28A2Q34057390-615EB27E-A5F8-45DE-B460-BC09053BC09DQ34058346-77F5C02C-522A-4714-8EDF-CA0C69533662Q34063375-AF92D612-AFC6-4CBD-BDDD-3FD43AA1214DQ34186939-4321D51D-CDAD-42F8-9887-443BCB3336C4Q34189102-DEE321DA-AE6C-4210-86E5-E901F695B5DFQ34193839-A2331A44-E8BE-4979-A008-AB134E0BD7A3Q34223613-63F3716B-4B13-472D-8E57-511A4D6DE536Q34235116-A1ADF316-DC5E-4004-83B1-A64860728409Q34293591-418F1A5A-E59D-482D-A0A8-93EE4B3F4316Q34544598-C98AD0DF-5AB7-4C86-9670-C70002355DFCQ34570937-D3672621-7CF9-44B9-9898-8371D6F88583Q34594877-5181BE7A-D6F3-4E37-AEF4-8DDA34A51262Q34596526-2B1DF617-5E92-4064-8FD1-9859B1E89D15Q34626223-D48163C4-58BC-4E80-976B-28939B5587A8Q34639656-8C9D0CD4-6C6E-4F34-85C6-DF9416845AA5
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Diagnosing model diagnostics.
@en
type
label
Diagnosing model diagnostics.
@en
prefLabel
Diagnosing model diagnostics.
@en
P356
P1476
Diagnosing model diagnostics.
@en
P2093
P356
10.1038/SJ.CLPT.6100241
P407
P577
2007-07-01T00:00:00Z